LEAP2KIDSNCT07927140
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percent change from baseline in magnetic resonance imaging(MRI) spleen volume (in multiples of normal [MN]) at Week 52
Timeframe: at Week 52
Secondary (8)
Percent change from baseline in MRI liver volume (in MN) at Week 52
Change from baseline in hemoglobin level at Week 52
Percent change from baseline in platelet count at Week 52
Changes from baseline in Vineland Adaptive Behavior Scales III Adaptive Behavior Composite (ABC) score at Week 52
Change from baseline in Vineland Adaptive Behavior Scale (VABS) III motor skill score at Week 52
Show 3 moreShow less
Percent change from baseline in plasma glucosylceramide (GL-1), glucosylsphingosine (lyso-GL-1), and other potential biomarker levels to Week 52
Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)
Plasma venglustat Ctrough at prespecified visits
Arms and interventions
VenglustatExperimental
Oral venglustat QD for 52 weeks in an open-label design for Primary Treatment Period followed by oral venglustat QD for 52 weeks in the Extension Treatment Period
CerezymeActive comparator
Primary Treatment Period: Cerezyme infusion every 2 weeks for 52 weeks
Drugs: Venglustat, Imiglucerase